These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38575808)

  • 1. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
    Mori S; Izumi H; Araki M; Liu J; Tanaka Y; Kagawa Y; Sagae Y; Ma B; Isaka Y; Sasakura Y; Kumagai S; Sakae Y; Tanaka K; Shibata Y; Udagawa H; Matsumoto S; Yoh K; Okuno Y; Goto K; Kobayashi SS
    Commun Biol; 2024 Apr; 7(1):412. PubMed ID: 38575808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
    Izumi H; Matsumoto S; Liu J; Tanaka K; Mori S; Hayashi K; Kumagai S; Shibata Y; Hayashida T; Watanabe K; Fukuhara T; Ikeda T; Yoh K; Kato T; Nishino K; Nakamura A; Nakachi I; Kuyama S; Furuya N; Sakakibara-Konishi J; Okamoto I; Taima K; Ebi N; Daga H; Yamasaki A; Kodani M; Udagawa H; Kirita K; Zenke Y; Nosaki K; Sugiyama E; Sakai T; Nakai T; Ishii G; Niho S; Ohtsu A; Kobayashi SS; Goto K
    Nature; 2021 Dec; 600(7888):319-323. PubMed ID: 34819663
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
    J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The
    Ibrahim R; Chahine C; Felefly T; Khalife N; Saleh K
    Future Oncol; 2023 Feb; 19(4):273-275. PubMed ID: 36942735
    [No Abstract]   [Full Text] [Related]  

  • 5. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
    Okada K; Araki M; Sakashita T; Ma B; Kanada R; Yanagitani N; Horiike A; Koike S; Oh-Hara T; Watanabe K; Tamai K; Maemondo M; Nishio M; Ishikawa T; Okuno Y; Fujita N; Katayama R
    EBioMedicine; 2019 Mar; 41():105-119. PubMed ID: 30662002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
    Xie B; Qiu Y; Zhou J; Du D; Ma H; Ji J; Zhu L; Zhang W
    Clin Transl Oncol; 2022 Nov; 24(11):2231-2240. PubMed ID: 35852680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.
    Jóri B; Falk M; Hövel I; Weist P; Tiemann M; Heukamp LC; Griesinger F
    Curr Oncol; 2022 Sep; 29(9):6628-6634. PubMed ID: 36135089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and clinical properties of lorlatinib in the treatment of
    El Darsa H; Abdel-Rahman O; Sangha R
    Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer.
    Taniguchi H; Akagi K; Dotsu Y; Yamada T; Ono S; Imamura E; Gyotoku H; Takemoto S; Yamaguchi H; Sen T; Yano S; Mukae H
    Cancer Sci; 2023 Jan; 114(1):164-173. PubMed ID: 36086904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound
    Yoda S; Lin JJ; Lawrence MS; Burke BJ; Friboulet L; Langenbucher A; Dardaei L; Prutisto-Chang K; Dagogo-Jack I; Timofeevski S; Hubbeling H; Gainor JF; Ferris LA; Riley AK; Kattermann KE; Timonina D; Heist RS; Iafrate AJ; Benes CH; Lennerz JK; Mino-Kenudson M; Engelman JA; Johnson TW; Hata AN; Shaw AT
    Cancer Discov; 2018 Jun; 8(6):714-729. PubMed ID: 29650534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
    Shiba-Ishii A; Johnson TW; Dagogo-Jack I; Mino-Kenudson M; Johnson TR; Wei P; Weinrich SL; McTigue MA; Walcott MA; Nguyen-Phuong L; Dionne K; Acker A; Kiedrowski LA; Do A; Peterson JL; Barth JL; Yeap BY; Gainor JF; Lin JJ; Yoda S; Hata AN
    Nat Cancer; 2022 Jun; 3(6):710-722. PubMed ID: 35726063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lorlatinib as a treatment for ALK-positive lung cancer.
    Baba K; Goto Y
    Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
    Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
    Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
    Zhang X; Tong J; Wang T; Wang T; Xu L; Wang Z; Hou T; Pan P
    Comput Biol Med; 2024 Feb; 169():107815. PubMed ID: 38128254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LTK fusions: A new target emerges in non-small cell lung cancer.
    Cooper AJ; Sequist LV; Johnson TW; Lin JJ
    Cancer Cell; 2022 Jan; 40(1):23-25. PubMed ID: 35016028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-Line Lorlatinib or Crizotinib in Advanced
    Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ;
    N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.